
Nitya Raj, MD, discusses the results of a phase 4 trial comparing injection site pain with octreotide long-acting release vs lanreotide in well-differentiated neuroendocrine tumors.

Nitya Raj, MD, discusses the results of a phase 4 trial comparing injection site pain with octreotide long-acting release vs lanreotide in well-differentiated neuroendocrine tumors.